Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera.

European journal of internal medicine - 1 Jun 2017

Rottenstreich A, Kleinstern G, Krichevsky S, Varon D, Lavie D, Kalish Y

Abstract excerpt

OBJECTIVE: We characterized acquired von Willebrand syndrome (AVWS) among essential thrombocythemia (ET) and polycythemia vera (PV) patients. METHODS: A review of patients with ET or PV evaluated for AVWS. RESULTS: Of 116 patients with ET, 64 (55%) developed AVWS; of 57 with PV, 28 (49%) developed AVWS. Median platelet counts of ET and PV patients who developed AVWS were 920×109/L and 679×109/L, respectively...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Calreticulin
Share to Hemorrhage

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Israel

Share to Platelet Count

Share to Polycythemia Vera

Share to Thrombocythemia, Essential

Share to von Willebrand Diseases

Share to von Willebrand Factor

Source

Identifiers

PMID: 27919526
DOI: 10.1016/j.ejim.2016.11.011

Genes

JAK2
VWF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera.PMID 27919526Read ↗

von Willebrand factor activity levels are influenced by driver mutation status in polycythemia vera and essential thrombocythemia patients with well-controlled platelet counts.Semantic proximity Read ↗

Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.Semantic proximity Read ↗

Estimation of diagnosis and prognosis in ET by assessment of CALR and JAK2V617F mutations and laboratory findings: a meta-analysis.Semantic proximity Read ↗

[Vascular complications of essential thrombocythemia].Semantic proximity Read ↗

Risk factors for thrombosis and bleeding and their influence on therapeutic decisions in patients with essential thrombocythemia.Semantic proximity Read ↗

Low-hemoglobin Polycythemia Vera: Diagnostic Criteria and Clinico-pathological CharacterizationSemantic proximity Read ↗

Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era.Semantic proximity Read ↗

Essential thrombocythemia A retrospective case series.Semantic proximity Read ↗

Incidence rates and risk factors for vascular events in patients with essential thrombocythemia: a multicenter study from Korea.Semantic proximity Read ↗

JAK2V617F mutation and circulating extracellular vesicles in essential thrombocythemia.Semantic proximity Read ↗

von Willebrand Disease: A Concise Review and Update for the Practicing Physician.Semantic proximity Read ↗

The 2014 BCSH criteria and the 2016 WHO criteria for essential thrombocythemia: A comparison in a large-scale cohort.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.